A Phase 3 interventional study of niraparib and Physician's choice in Neoplasms, Breast, Carcinoma of Breast and Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, sponsored by Tesaro, Inc.. Terminated at 104 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-15.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing niraparib in Breast Neoplasms — 6 open to participants now, 11 under way, 1 of them phase 3. niraparib · Breast Neoplasms.
Among the 20 studies testing niraparib in Breast Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2014, is one of 2 in phase 3, and was the 2nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →6 of the 20 studies testing niraparib in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Nagoya City University · Sites in Japan
Ages 18–80
Canadian Cancer Trials Group · Sites in Canada
GlaxoSmithKline · Sites in United States, Austria, Canada and 5 more countries
Ages 18+
QuantumLeap Healthcare Collaborative · Sites in United States
Ages 18+
Institut Paoli-Calmettes
Ages 18+
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 3 2
First in 2010; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 27 across the 20 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tesaro, Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
59 studies in Breast Neoplasms by GlaxoSmithKline: 1 open now, 3 under way, 1 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Breast Neoplasms by GlaxoSmithKline, this one is the 6th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 51st registered.
GlaxoSmithKline’s Breast Neoplasms studies by the year they started, since 2002.
6 of the studies testing niraparib in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
| NCT03945721Massachusetts General HospitalA Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | 2026-12-31 |
| NCT04837209Massachusetts General HospitalRadiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer | 2027-02-01 |
| NCT06535893Nagoya City UniversitySustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer | 2027-06-30 |
| NCT05519670Institut Paoli-CalmettesA Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies testing niraparib in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 59 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice
This is a phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients. Niraparib is an orally active PARP inhibitor. Niraparib (in a 2:1 ratio) will be administered once daily continuously during a 21-day cycle. Physician's choice will be administered on a 21-day cycle. Health-related quality of life will be measured. The safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety laboratory values.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior therapy should have included a taxane and/or anthracycline (unless to those) in the neoadjuvant, adjuvant, or advanced/metastatic setting.
a. Hormone receptor positive patients must also have hormone resistant disease; either relapsed while on adjuvant endocrine treatment, or within one year of completing adjuvant endocrine treatment, or progression on at least one line of endocrine treatment for advanced cancer.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Physician may select from 4 active comparators
Drug: Physician's choice
Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days
Drug: niraparib
300 mg (3x100 mg capsules) once daily until progression or unacceptable toxicity develops
Also known as: formerly MK-4827
Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
Progression Free Survival (PFS) - Central Review Assessment
The primary objective of this study is to compare progression-free survival (PFS), as assessed by blinded central review, of participants with advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gBRCA mutation breast cancer when treated with niraparib as compared to those treated with physician's choice single agent chemotherapy standards (eribulin, vinorelbine, gemcitabine or capecitabine). PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per Response evaluation criteria in solid tumors (RECIST) version (v)1.1 as determined by central review assessment. Progressive Disease is defined as at least a 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 millimeter (mm).
Time frame: From the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier, up to 4 years
Overall Survival
Overall Survival (OS) was defined as the time from randomization to the date of death of any causes.
Time frame: From treatment randomization to date of death of any cause, up to 4 years
Number of Participants With Central BRCA Mutation Status
Blood samples were collected to evaluate central BRCA mutation status of participants. Baseline was defined as the most recent non-missing measurement prior to or on the first administration of study drug. Number of participants with central BRCA mutation status as BRCA1 positive only, BRCA2 positive only, Rearrangement only, BRCA1 and BRCA2 positive, BRCA1 positive and rearrangement, and BRCA2 positive and rearrangement were reported.
Time frame: At Baseline (Cycle 1 Day1) (Cycle duration was 21 days)
Number of Participants With Serious Adverse Events (SAE) and Non-serious Adverse Events (Non-SAE)
An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect in a participant, whether or not considered related to the protocol treatment, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing participant hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an medically important event or reaction as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.
Time frame: Up to 7 years
Progression Free Survival (PFS) - Investigator Assessment
PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per RECIST version 1.1 as determined by Investigator assessment. Progressive Disease is defined as at least a 20 % increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 mm.
Time frame: Assessed up to 4 years
Time to Treatment Failure
Time to treatment failure was defined from the date of randomization to progression or discontinuation of treatment for any reason, including but not restricted to disease progression, treatment toxicity and death.
Time frame: Date of randomization to discontinuation of treatment for any reason, up to 4 years
Overall Response Rate (ORR)
ORR was defined as the percentage of the participants who achieved a complete response (CR) or partial response (PR) to treatment evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR)=disappearance of all target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial Response (PR)= at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the Baseline sum of diameters. Percentage values are rounded off up to 1 decimal.
Time frame: Up to 4 years
Duration of Response (DOR)
Duration of response was defined as the time from first documentation of response (confirmed CR or PR) until the time of first documentation of disease progression by RECIST v1.1 or death by any cause.
Time frame: Up to 4 years
Number of Participants With Serious Adverse Events Related to New Malignancy
The number of participants with serious adverse events related to new malignancy were reported.
Time frame: Up to 7 years
Number of Participants With Subsequent Anticancer Therapies
The number of participants with subsequent anticancer therapies were evaluated. Data has been reported as per following categories: any new anitumoral therapy, any chemotherapy, any radiotherapy, any surgery, any hormonal therapy, any targeted agents, and any other treatment. Participants may have received more than one subsequent therapies.
Time frame: Up to 7 years
Number of Participants With Minimally Clinically Important Difference (MCID) Status in European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire-C30 (EORTC-QLQ-C30)
The number of participants with MCID status in EORTC-QLQ-C30 was planned to be evaluated.The EORTC- QLQ-C30 includes 30-items with single and multi-item scales. These include five functional scales (physical functioning, role functioning cognitive functioning, emotional functioning and social functioning), three symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options are 1 to 4. The average score can be transformed to 0 to 100, a high score for functional scales/ GHS/QoL represents better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represents significant symptomatology.
Time frame: Up to 7 years
Number of Participants With Euroqol 5 Dimension 5 Level (EQ-5D-5L) Dimension Scores by Visit
The number of participants with EQ-5D-5L scores by visit were planned to be evaluated. EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were to be converted to a single index score. Range for EQ-5D-5L index score is 0 (worst health) to 100 (best health), higher the score better the health status.
Time frame: Up to 7 years
Number of Participants With Any Subsequent Therapies Post Discontinuation of Study Treatment and Association With Potential Survival Related Outcomes
The number of participants with any subsequent therapies post-discontinuation of study treatment and association with potential survival related outcomes were planned to be evaluated.
Time frame: Up to 7 years
Number of Participants With Presence of Genetic and Non-genetic Biomarkers
Biomarkers include germline and tumor mutations including somatic BRCA1 and 2 mutations, reversion mutations, loss of heterozygosity as well as genome landscape and transcriptional or functional measures of homologous recombination (HR) deficiency were planned to be evaluated.
Time frame: Up to 7 years
Number of Participants With Germline BRCA1 and BRCA2 Mutation Status in Association With Survival Related Outcomes
Participants with germline BRCA1 and BRCA2 mutation status in association with survival related outcomes were planned to be evaluated.
Time frame: Up to 7 years
Previously treated, human epidermal growth factor receptor 2 HER2 negative, germline Breast Cancer gene (gBRCA) mutation positive breast cancer participants were enrolled. The study was terminated due to futility.
| Milestone | Physician's Choice | Niraparib |
|---|---|---|
| Started | 71 | 135 |
| Completed | 0 | 0 |
| Not completed | 71 | 135 |
| Withdrew: Disease progression | 51 | 110 |
| Withdrew: Toxicity | 1 | 16 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Start of new anti-cancer treatment | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Sponsor's decision | 1 | 1 |
| Withdrew: Not treated | 7 | 3 |
| Withdrew: Withdrawal by subject | 10 | 2 |
The primary objective of this study is to compare progression-free survival (PFS), as assessed by blinded central review, of participants with advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gBRCA mutation breast cancer when treated with niraparib as compared to those treated with physician's choice single agent chemotherapy standards (eribulin, vinorelbine, gemcitabine or capecitabine). PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per Response evaluation criteria in solid tumors (RECIST) version (v)1.1 as determined by central review assessment. Progressive Disease is defined as at least a 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 millimeter (mm).
| Months | Physician's Choice | Niraparib |
|---|---|---|
| Progression Free Survival (PFS) - Central Review Assessment | 3.1 (1.6 to 7.2) | 4.1 (2.9 to 4.5) |
Overall Survival (OS) was defined as the time from randomization to the date of death of any causes.
| Months | Physician's Choice | Niraparib |
|---|---|---|
| Overall Survival | 15.8 (12.1 to 18.4) | 14.5 (11.7 to 17.2) |
Blood samples were collected to evaluate central BRCA mutation status of participants. Baseline was defined as the most recent non-missing measurement prior to or on the first administration of study drug. Number of participants with central BRCA mutation status as BRCA1 positive only, BRCA2 positive only, Rearrangement only, BRCA1 and BRCA2 positive, BRCA1 positive and rearrangement, and BRCA2 positive and rearrangement were reported.
| Participants | Physician's Choice | Niraparib |
|---|---|---|
| BRCA1 positive only | 38 | 66 |
| BRCA2 positive only | 28 | 57 |
| Rearrangement only | 3 | 7 |
| BRCA1 and BRCA2 positive | 1 | 3 |
| BRCA1 positive and rearrangement | 1 | 1 |
| BRCA2 positive and rearrangement | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence or effect in a participant, whether or not considered related to the protocol treatment, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing participant hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an medically important event or reaction as per medical and scientific judgment. Adverse events which were not serious adverse events were considered as non serious adverse events.
| Participants | Physician's Choice | Niraparib |
|---|---|---|
| SAE | 4 | 33 |
| Non-SAE | 62 | 134 |
PFS is defined as the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier as per RECIST version 1.1 as determined by Investigator assessment. Progressive Disease is defined as at least a 20 % increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including Baseline) and an absolute increase of \>= 5 mm.
| Months | Physician's Choice | Niraparib |
|---|---|---|
| Progression Free Survival (PFS) - Investigator Assessment | 3.1 (2.7 to 5.1) | 5.0 (4.2 to 5.5) |
Time to treatment failure was defined from the date of randomization to progression or discontinuation of treatment for any reason, including but not restricted to disease progression, treatment toxicity and death.
| Months | Physician's Choice | Niraparib |
|---|---|---|
| Time to Treatment Failure | 2.6 (1.6 to 3.2) | 4.3 (4.0 to 5.5) |
ORR was defined as the percentage of the participants who achieved a complete response (CR) or partial response (PR) to treatment evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR)=disappearance of all target and non-target lesions and normalization of tumor markers. Pathological lymph nodes must have short axis measures \<10 mm. Partial Response (PR)= at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of target lesions, taking as reference the Baseline sum of diameters. Percentage values are rounded off up to 1 decimal.
| Percentage of participants | Physician's Choice | Niraparib |
|---|---|---|
| Overall Response Rate (ORR) | 12.5 (5.6 to 23.2) | 21.4 (14.6 to 29.6) |
Duration of response was defined as the time from first documentation of response (confirmed CR or PR) until the time of first documentation of disease progression by RECIST v1.1 or death by any cause.
| Months | Physician's Choice | Niraparib |
|---|---|---|
| Duration of Response (DOR) | 5.65 (5.65 to 14.78) | 4.14 (2.79 to 6.90) |
The number of participants with MCID status in EORTC-QLQ-C30 was planned to be evaluated.The EORTC- QLQ-C30 includes 30-items with single and multi-item scales. These include five functional scales (physical functioning, role functioning cognitive functioning, emotional functioning and social functioning), three symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhea, insomnia, dyspnea, appetite loss and financial difficulties). Response options are 1 to 4. The average score can be transformed to 0 to 100, a high score for functional scales/ GHS/QoL represents better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represents significant symptomatology.
No measurements were reported for this outcome.
The number of participants with EQ-5D-5L scores by visit were planned to be evaluated. EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility,self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale(no problems, slight problems, moderate problems, severe problems and extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were to be converted to a single index score. Range for EQ-5D-5L index score is 0 (worst health) to 100 (best health), higher the score better the health status.
No measurements were reported for this outcome.
The number of participants with any subsequent therapies post-discontinuation of study treatment and association with potential survival related outcomes were planned to be evaluated.
No measurements were reported for this outcome.
Biomarkers include germline and tumor mutations including somatic BRCA1 and 2 mutations, reversion mutations, loss of heterozygosity as well as genome landscape and transcriptional or functional measures of homologous recombination (HR) deficiency were planned to be evaluated.
No measurements were reported for this outcome.
Participants with germline BRCA1 and BRCA2 mutation status in association with survival related outcomes were planned to be evaluated.
No measurements were reported for this outcome.
The number of participants with serious adverse events related to new malignancy were reported.
| Participants | Physician's Choice | Niraparib |
|---|---|---|
| Number of Participants With Serious Adverse Events Related to New Malignancy | 0 | 2 |
The number of participants with subsequent anticancer therapies were evaluated. Data has been reported as per following categories: any new anitumoral therapy, any chemotherapy, any radiotherapy, any surgery, any hormonal therapy, any targeted agents, and any other treatment. Participants may have received more than one subsequent therapies.
| Participants | Physician's Choice | Niraparib |
|---|---|---|
| Any new antitumoral therapy | 55 | 108 |
| Any chemotherapy | 48 | 96 |
| Any radiotherapy | 22 | 48 |
| Any surgery | 5 | 13 |
| Any hormonal therapy | 13 | 27 |
| Any targeted agent therapy | 19 | 22 |
| Any other treatment | 8 | 17 |
Collected over All-cause mortality, Serious adverse events (SAEs) and non-serious AEs (non-SAEs) were collected up to 7 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Physician's Choice | 39/65 (60%) | 4/65 (6.2%) | 62/65 (95.4%) |
| Niraparib | 79/134 (59%) | 33/134 (24.6%) | 134/134 (100%) |
| Event | Physician's Choice | Niraparib |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/65 | 10/134 |
| AnaemiaBlood and lymphatic system disorders | 0/65 | 9/134 |
| NauseaGastrointestinal disorders | 0/65 | 5/134 |
| PneumoniaInfections and infestations | 0/65 | 4/134 |
| VomitingGastrointestinal disorders | 1/65 | 3/134 |
| HeadacheNervous system disorders | 0/65 | 3/134 |
| PainGeneral disorders | 1/65 | 1/134 |
| PyrexiaGeneral disorders | 1/65 | 1/134 |
| HypoaesthesiaNervous system disorders | 1/65 | 1/134 |
| Language disorderNervous system disorders | 1/65 | 0/134 |
| Event | Physician's Choice | Niraparib |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 23/65 | 91/134 |
| NauseaGastrointestinal disorders | 24/65 | 82/134 |
| FatigueGeneral disorders | 29/65 | 66/134 |
| Weight decreasedInvestigations | 10/65 | 53/134 |
| VomitingGastrointestinal disorders | 11/65 | 51/134 |
| ConstipationGastrointestinal disorders | 11/65 | 48/134 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/65 | 48/134 |
| DiarrhoeaGastrointestinal disorders | 22/65 | 19/134 |
| HeadacheNervous system disorders | 10/65 | 44/134 |
| Platelet count decreasedInvestigations | 3/65 | 43/134 |
The centrally-confirmed intent-to-treat population is defined as all randomized participants with a central confirmation of germline BRCA mutation.
| Age, Customized(Participants) | Physician's Choice | Niraparib | Total |
|---|---|---|---|
| 18-64 years | 67 | 127 | 194 |
| 65-74 years | 3 | 5 | 8 |
| >=75 years | 1 | 3 | 4 |
| Sex: Female, Male(Participants) | Physician's Choice | Niraparib | Total |
|---|---|---|---|
| Female | 68 | 135 | 203 |
| Male | 3 | 0 | 3 |
| Ethnicity (NIH/OMB)(Participants) | Physician's Choice | Niraparib | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 50 | 110 | 160 |
| Unknown or Not Reported | 15 | 19 | 34 |
| Race/Ethnicity, Customized(Participants) | Physician's Choice | Niraparib | Total |
|---|---|---|---|
| Race — Ashkenazi Jewish descendant | 6 | 5 | 11 |
| Race — White or Caucasian | 59 | 108 | 167 |
| Race — Black | 3 | 6 | 9 |
| Race — Asian | 0 | 2 | 2 |
| Race — Unknown | 1 | 7 | 8 |
| Race — Missing | 2 | 7 | 9 |
Showing the first 100 of 104 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2014 to primary completion in May 2018, 50 months.
Results were first posted in Aug 2020, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niraparib